Abstracts tagged "osteoarthritis and treatment"

Abstract Number: 442 • 2018 ACR/ARHP Annual Meeting
Patient Factors Associated with Gaps in Osteoarthritis Care
Lauren King¹, Deborah A. Marshall² and Gillian Hawker³, ¹University of Toronto, Canada, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Community Health Sciences, University of Calgary, Calgary, AB, Canada, ³Women's College Research Institute/Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Exercise, weight loss, simple analgesic medications and joint injections are effective non-surgical treatments for knee osteoarthritis (OA) to reduce pain and improve function. While…
Abstract Number: 1055 • 2018 ACR/ARHP Annual Meeting
The TLR-4 Inhibitor 6-Shogaol As a Treatment in Osteoarthritis Trough the Modulation of Chondrocyte Hypertrophy and Matrix Calcification
Paula Gratal¹, Aranzazu Mediero², Ana Lamuedra¹, Raquel Largo¹ and Gabriel Herrero-Beaumont¹, ¹Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain, ²Joint and Bone Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Osteoarthritis (OA) is a complex joint disease characterized by a progressive loss of articular cartilage (AC) and synovial inflammation. The latest theories of OA…
Abstract Number: 1194 • 2017 ACR/ARHP Annual Meeting
Are Bisphosphonates Efficacious in Knee Osteoarthritis? A Meta-Analysis of Randomized Controlled Trials
Mikala C. Osani¹, Elizaveta Vaysbrot¹, Raveendhara R. Bannuru², Mia-Cara Musetti¹ and Timothy E. McAlindon¹, ¹Division of Rheumatology, Tufts Medical Center, Boston, MA, ²Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: One of the key aspects of osteoarthritis (OA) pathogenesis is subchondral bone remodeling. Bisphosphonates have been touted as disease-modifying agents for OA due to…
Abstract Number: 315 • 2015 ACR/ARHP Annual Meeting
Structural Effects of Sprifermin in Knee Osteoarthritis: A Post-Hoc Analysis on Cartilage and Non-Cartilaginous Tissue Alterations
Frank Roemer¹, Aida Aydemir², Stefan Lohmander³, Michel Crema⁴, Monica D. Marra⁵, Norma Muurahainen², Felix Eckstein⁶ and Ali Guermazi⁷, ¹Radiology, Boston University School of Medicine, Boston, MA, ²EMD Serono, Billerica, MA, ³Lund University, Lund, Sweden, ⁴Department of Radiology, Boston University School of Medicine, Boston, MA, ⁵Department of Radiology, BUSM, Boston, MA, ⁶Paracelsus Med Univ, Chondrometrics GmbH, Salzburg, Austria, ⁷Boston University School of Medicine, Boston, MA
Background/Purpose: A randomized, double-blind, placebo-controlled phase 1b clinical trial of sprifermin (rhFGF18) in knee OA assessed central medial tibio-femoral compartment cartilage thickness on quantitative MRI…
Abstract Number: 2240 • 2014 ACR/ARHP Annual Meeting
An Exploratory 4-Week Study of a P2X3 Antagonist AF-219 in the Treatment of Patients with Osteoarthritis (OA) of the Knee
Vibeke Strand¹, Michael Kitt², Alan Kivitz³, Anthony Ford², Peter Butera² and Bruce McCarthy², ¹Stanford University, Portola Valley, CA, ²Afferent Pharmaceuticals, Inc., San Mateo, CA, ³Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose Targeting P2X3 receptors that mediate the sensitizing effects of ATP released from inflamed and damaged tissues on the primary afferent neurons (PAN) of musculoskeletal…
Abstract Number: 1019 • 2014 ACR/ARHP Annual Meeting
Targeting the Bone-Driven Metabolic OA Phenotype By a Novel Dual Amylin Calcitonin Receptor Agonist, KBP-056
Ditte Reker, Sara Toftegaard Hjuler, Kim Andreassen, Morten Asser Karsdal, Kim Henriksen and Anne C. Bay-Jensen, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) may be segregated into different disease phenotypes based on disease drivers; cartilage damage, joint inflammation or subchondral bone remodelling. Each phenotype may…
Abstract Number: 2251 • 2014 ACR/ARHP Annual Meeting
Kneeling Disability Associated with the Treatment of Osteoarthritis: Analysis of a Copcord Study in Mexico
Alexia Hernández-Cáceres¹, Jacqueline Rodríguez-Amado¹, Ingris Peláez-Ballestas², David Vega-Morales³, Mario Garza-Elizondo¹, Roberto Negrete-López¹, Lorena Pérez-Barbosa¹ and Janett Riega-Torres¹, ¹Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Departamento de Reumatología, Departamento de Reumatología Hospital General de México “Dr. Eduardo Liceaga”, Distrito Federal, Mexico, ³Rheumatology, Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose Osteoarthritis (OA) is the most prevalent rheumatic disease in Mexico. The core treatment, a combination of pharmacological and non-pharmacological modalities, is mainly performed in…
Abstract Number: 2151 • 2013 ACR/ARHP Annual Meeting
Synergistic Effect of Combining BioniCare® in an Unloading Brace for Osteoarthritis of the Knee
Thomas Zizic¹, David S. Hungerford², Edmund J. MacLaughlin³, Craig Mines⁴, Shaili Deveshwar⁵, Theresa Lawrence Ford⁶, Cynthia Elliott⁶, John R. Principe⁷, Jack S. Tuber⁸ and Joy Schechtman⁹, ¹Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Ortho Surgery, Johns Hopkins University, Baltimore, MD, ³The Johns Hopkins University School of Medicine, Cambridge, MD, ⁴East Side OrthoCare, Snellville, GA, ⁵Sports Medicine and Orthopedic Center, Greensboro, NC, ⁶North Georgia Rheumatology, Lawrenceville, GA, ⁷WellBeingMD, Palos Heights, IL, ⁸The Johns Hopkins University, Baltimore, Maryland, Baltimore, MD, ⁹SunValley Arthritis Center, Peoria, AZ
Background/Purpose: The purpose of this study was to see if incorporating the BioniCare device into an unloading brace would produce more rapid improvement, greater compliance…
Abstract Number: 2140 • 2013 ACR/ARHP Annual Meeting
Effects Of Intra-Articular Hyaluronic Acid Injections On Gait Pattern In Patients With Knee Osteoarthritis
Bilal Uysal¹, Aysegul Ketenci², Sina Esmaeilzadeh² and Dilsad Sindel², ¹Physical Medicine And Rehabilitation, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Physical Medicine and Rehabilitation, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The aim of this study was to determine the effects of intra-articular hyaluronic acid (HA) injections on gait pattern of both injected and un-injected…
Abstract Number: 53 • 2013 ACR/ARHP Annual Meeting
Adenosine A_2A Receptor As a Potential New Therapeutic Target For The Prevention/Treatment Of Osteoarthritis
Aranzazu Mediero¹, Tuere Wilder² and Bruce N. Cronstein³, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, ³Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Osteoarthritis, the most common type of arthritis in the United States, results from trauma and other mechanical factors as well as metabolic changes in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].